KR20230020560A - 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 - Google Patents

정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 Download PDF

Info

Publication number
KR20230020560A
KR20230020560A KR1020237002817A KR20237002817A KR20230020560A KR 20230020560 A KR20230020560 A KR 20230020560A KR 1020237002817 A KR1020237002817 A KR 1020237002817A KR 20237002817 A KR20237002817 A KR 20237002817A KR 20230020560 A KR20230020560 A KR 20230020560A
Authority
KR
South Korea
Prior art keywords
cancer
inhibitor
cells
compound
mitotic inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237002817A
Other languages
English (en)
Korean (ko)
Inventor
마리아 빌렌칙
마이클 프라이드
알렉산드라 쿠즈넷소바
유리이 간킨
마크 듀이
Original Assignee
펠리시텍스 쎄라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펠리시텍스 쎄라퓨틱스, 인코포레이티드 filed Critical 펠리시텍스 쎄라퓨틱스, 인코포레이티드
Publication of KR20230020560A publication Critical patent/KR20230020560A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237002817A 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합 Ceased KR20230020560A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662323583P 2016-04-15 2016-04-15
US62/323,583 2016-04-15
PCT/US2017/027734 WO2017181087A1 (en) 2016-04-15 2017-04-14 Combinations for the treatment of neoplasms using quiescent cell targeting and inhibitors of mitosis
KR1020187033030A KR102494172B1 (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187033030A Division KR102494172B1 (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Publications (1)

Publication Number Publication Date
KR20230020560A true KR20230020560A (ko) 2023-02-10

Family

ID=60039311

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237002817A Ceased KR20230020560A (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합
KR1020187033030A Active KR102494172B1 (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187033030A Active KR102494172B1 (ko) 2016-04-15 2017-04-14 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합

Country Status (11)

Country Link
US (3) US10314843B2 (https=)
EP (1) EP3443351A4 (https=)
JP (1) JP7278776B2 (https=)
KR (2) KR20230020560A (https=)
CN (1) CN109313197A (https=)
AU (2) AU2017248807A1 (https=)
BR (1) BR112018071023A2 (https=)
CA (1) CA3020978A1 (https=)
IL (2) IL292475A (https=)
MX (2) MX2018012508A (https=)
WO (1) WO2017181087A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3021021A1 (en) * 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598758A (en) * 2009-09-11 2013-12-20 Amgen Inc N-4 (-((3-(2-amino-4 pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
US20120184562A1 (en) 2011-01-19 2012-07-19 Kin-Chun Luk 1,6- and 1,8-naphthyridines
US9446044B2 (en) * 2011-08-19 2016-09-20 Diaxonhit DYRK1 inhibitors and uses thereof
FR2993317B1 (fr) 2012-07-16 2014-08-15 Snecma Carter de turbomachine dans un materiau composite et procede de fabrication associe
JP2015534584A (ja) * 2012-10-10 2015-12-03 フェリシテックス・セラピューティクス，インコーポレイテッド 静止癌細胞の標的化による癌の治療
TN2015000543A1 (en) * 2013-06-11 2017-04-06 Bayer Pharma AG Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor
CA2854542A1 (en) * 2013-06-18 2014-12-18 4Sc Discovery Gmbh Method of inhibiting dyrk1b
US9566280B2 (en) * 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
CN106535890A (zh) * 2014-03-20 2017-03-22 萨穆梅德有限公司 5‑取代的吲唑‑3‑羧酰胺及其制备和应用
US20170304313A1 (en) 2014-10-06 2017-10-26 Novartis Ag Therapeutic Combination For The Treatment Of Cancer
ES2917526T3 (es) * 2015-07-23 2022-07-08 Calgent Biotechnology Co Ltd Compuestos de aminonaptoquinona y composición farmacéutica para bloquear el sistema ubiquitinación-proteasoma en enfermedades
CA3021021A1 (en) 2016-04-15 2017-10-19 Felicitex Therapeutics, Inc. Combinations for the treatment of neoplasms using quiescent cell targeting and egfr inhibitors

Also Published As

Publication number Publication date
US20170296542A1 (en) 2017-10-19
JP2019511553A (ja) 2019-04-25
US20220110941A1 (en) 2022-04-14
CA3020978A1 (en) 2017-10-19
IL262325A (en) 2018-11-29
MX2022012146A (es) 2022-10-21
CN109313197A (zh) 2019-02-05
EP3443351A1 (en) 2019-02-20
AU2017248807A1 (en) 2018-10-25
US10314843B2 (en) 2019-06-11
AU2023214240A1 (en) 2023-08-24
KR20180130575A (ko) 2018-12-07
BR112018071023A2 (pt) 2019-02-05
KR102494172B1 (ko) 2023-02-02
IL262325B (en) 2022-06-01
JP7278776B2 (ja) 2023-05-22
IL292475A (en) 2022-06-01
US20190290651A1 (en) 2019-09-26
MX2018012508A (es) 2019-07-08
WO2017181087A1 (en) 2017-10-19
EP3443351A4 (en) 2019-12-18

Similar Documents

Publication Publication Date Title
KR102494172B1 (ko) 정지 세포 표적화 및 유사분열 억제제를 이용하는 신생물 치료를 위한 조합
KR102494174B1 (ko) 정지 세포 표적화 및 egfr 억제제를 이용하는 신생물 치료를 위한 조합
US8138356B2 (en) Chemical inhibitors of inhibitors of differentiation
WO2023140846A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
Berte et al. Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence
Zheng et al. Simultaneous NF‐κB inhibition and E‐cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo
US20240409544A1 (en) SUBSTITUTED PYRROLO[1,2-a]QUINOXALIN-4(5H)-ONES AS CX3CR1 ANTAGONISTS
US20220073519A1 (en) Compounds For Repressing Cancer Cell Growth
AU2013235275A1 (en) Methods of treating cancer using aurora kinase inhibitors
MX2024013264A (es) Compuestos de 7-(pirimidin-4-il)quinolin-4(1h)-ona sustituidos como inhibidores de cinasas dependientes de ciclina
CA2986547C (en) A compound for anti-cancer therapy that acts by targeting gof mutant p53 and stimulates p73 to restore the p53 pathway signaling
US20230226061A1 (en) Combination cancer therapy with dyrk1 inhibitors and inhibitors of the ras-raf-mek-erk (mapk) pathway
JP2025530417A (ja) 腫瘍の予防・治療薬及びその用途
WO2017069913A1 (en) Chalcone compounds
WO2011131636A1 (en) Combined treatment of cancer with benzo[e]pyridoindoles and dna-damaging agents

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230125

Application number text: 1020187033030

Filing date: 20181114

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240205

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240510

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20240205

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I